News articles about Amdocs (NASDAQ:DOX) have trended positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amdocs earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news stories about the technology company an impact score of 46.0163267337718 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
DOX has been the subject of several research reports. BidaskClub raised Amdocs from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 18th. Zacks Investment Research cut Amdocs from a “buy” rating to a “hold” rating in a report on Wednesday. Jefferies Group upgraded Amdocs from a “hold” rating to a “buy” rating and decreased their target price for the stock from $71.37 to $60.20 in a report on Monday, March 19th. Oppenheimer reiterated a “buy” rating and set a $77.00 target price on shares of Amdocs in a report on Wednesday, January 31st. Finally, ValuEngine raised Amdocs from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $69.74.
Shares of NASDAQ:DOX traded down $1.32 on Friday, hitting $65.59. The company’s stock had a trading volume of 407,115 shares, compared to its average volume of 691,985. Amdocs has a 12 month low of $60.30 and a 12 month high of $71.72. The stock has a market cap of $9,596.43, a price-to-earnings ratio of 18.48, a PEG ratio of 2.27 and a beta of 0.54.
Amdocs (NASDAQ:DOX) last released its quarterly earnings results on Tuesday, January 30th. The technology company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.17. Amdocs had a return on equity of 15.13% and a net margin of 11.72%. The company had revenue of $977.70 million during the quarter, compared to analysts’ expectations of $979.13 million. During the same quarter in the prior year, the business posted $0.90 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities analysts expect that Amdocs will post 3.76 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 20th. Investors of record on Friday, March 30th will be paid a $0.25 dividend. This is an increase from Amdocs’s previous quarterly dividend of $0.22. This represents a $1.00 annualized dividend and a yield of 1.52%. The ex-dividend date is Wednesday, March 28th. Amdocs’s dividend payout ratio is currently 28.17%.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/positive-media-coverage-somewhat-unlikely-to-impact-amdocs-dox-stock-price.html.
Amdocs Limited is a provider of software and services for communications, entertainment and media industry service providers. The Company develops, implements and manages software and services associated with business support systems (BSS), operational support systems (OSS) and network operations to enable service providers to introduce new products and services, process orders, monetize data, support new business models and enhance their understanding of their customers.
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.